From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities
Cancer Nexus · 2026-07 · 2 (3)
DOI: 10.1002/cnx2.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Nexus, online erschienen am 02.06.2026. Verfasst von Xue Zhang und 4 weiteren Autor:innen. Die Arbeit nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling jointly sustain intestinal inflammation and contribute to carcinogenesis. The gut microbiota–immune microenvironment axis has therefore emerged as a critical mechanistic link between IBD and cancer development. Here, we summarize the roles of major immune cell populations—including macrophages, T cells, B cells, neutrophils, dendritic cells, innate lymphoid cells, and natural killer cells—in mediating the crosstalk between gut microbiota and the intestinal immune microenvironment. We further highlight the potential of natural products, particularly bioactive compounds derived from traditional Chinese medicine, to target this axis in IBD and IBD‐associated cancer. Through modulation of microbial composition, inflammatory signaling, immune cell function, and epithelial barrier integrity, these agents may provide therapeutic value in prevention, treatment, and adjuvant intervention. Elucidating the mechanisms underlying this regulatory axis may offer new opportunities for precision strategies in IBD and IBD‐associated cancer.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Gao, C., Jiang, R., Wu, Z., & Bai, J. (2026). From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities. Cancer Nexus, 2(3). https://doi.org/10.1002/cnx2.70030
Vancouver
Zhang X, Gao C, Jiang R, Wu Z, Bai J. From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities. Cancer Nexus. 2026;2(3). doi:10.1002/cnx2.70030
BibTeX
@article{Zhang2026,
author = {Zhang, Xue and Gao, Chongchong and Jiang, Rui and Wu, Zijian and Bai, Jian},
title = {From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities},
journal = {Cancer Nexus},
year = {2026},
volume = {2},
number = {3},
doi = {10.1002/cnx2.70030}
}
EUVIMED